Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer
This study is a Prospective, Single-arm, Phase 2 clinical trial. The purpose of this study is to find out if taking Utidelone Capsules together with Fruquintinib Capsules is safe and works well for people with platinum-resistant ovarian cancer . Researchers will look at the Objective Response Rate, Progression-Free Survival, Overall Survival, safety, and any side effects.
Platinum Resistant Ovarian Cancer
DRUG: Utidelone Capsules|DRUG: Fruquintinib Capsules
ORR, Objective response rate, according to RECIST v1.1, Up to 24 months
CA-125 remission rate, evaluated according to gcic CA-125 standard, Up to 24 months|PFS, Progression-free survival, according to RECIST v1.1, approximately 2 years|OS, Overall survival, according to RECIST v1.1, Up to 2 years|AEs, Adverse Events, according to CTCAE V5.0 criteria, During the trial, the adverse event record form should be truthfully filled in, including the occurrence time, severity, correlation with study treatment, duration, measures taken and outcome of the adverse event., From the first drug administration to within 30 days for the last treatment dose
This study is a Prospective, Single-arm, Phase 2 clinical trial. The purpose of this study is to find out if taking Utidelone Capsules together with Fruquintinib Capsules is safe and works well for people with platinum-resistant ovarian cancer . Researchers will look at the Objective Response Rate, Progression-Free Survival, Overall Survival, safety, and any side effects.